Chemoprevention of gastric cancer by H. pylori eradication or taking aspirin: analysis of molecular alterations
- Conditions
- Early gastric cancer/gastric adenoma
- Registration Number
- JPRN-UMIN000021857
- Lead Sponsor
- Hyogo College of Medicine, Division of Gasstroenterology, Department of Internal Medicine
- Brief Summary
In these studies, we evaluated the effects of H. pylori eradication and aspirin on genetic/epigenetic alterations in precancerous conditions, i.e., atrophic mucosa (AM) and intestinal metaplasia (IM), in patients with and without gastric cancer. DNA was extracted from goblet IM and AM separately using the laser capture microdissection. 1. H. pylori eradication was associated with significant reductions of methylation of several genes/loci in AM, but not in IM. In contrast, the incidence of CpG island methylator phenotype (CIMP) in IM was significantly higher in patients with gastric cancer than in those without. miR-124a-3 methylation and miR-34c methylation were more frequently identified in IM, with very few in AM.(Conclusions) H. pylori eradication can reverse methylation only AM. CIMP in IM may have potential as a surrogate maker of GC development, and methylation of miR-124a-3 and miR-34c is a molecular event in IM that may not be associated with GC development. 2. Aspirin use was associated with a significant reduction of CDH1 methylation in AM, but was less effective in reversing the methylation that occurred in IM. Frequent hypermethylation including that of CDH1 in AM increased in patients with gastric cancer compared to those without, and CDH1 methylation was an independent predictive marke of gastric cancer. (Conclusions) In patients with long-term aspirin use, the changes of molecular events in AM but not IM may be an important factor in the reduction of cancer incidence. In addition, methylation of the CDH1 gene in AM may be a surrogate of gastric cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
(1)Patients with malignancy in other organs. (2)Patients with having a past history of esophagectomy or gastrectomy. (3)Patients who have determined by the physicians to have any reasons of unqualified.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method